Author | Eric A. Klein, MD


Precision Medicine Approaches to the Diagnosis and Management of Prostate Cancer

February 15, 2014

For those undergoing screening for the presence of previously undiagnosed prostate cancer, the major challenge for new tests is to avoid the overdetection of indolent cancers that limits the clinical utility of the prostate-specific antigen (PSA) test.

Brachytherapy or Surgery? A Composite View

October 13, 2009

The comparison of brachytherapy and surgery may be done on several levels. This review focuses the comparison on toxicity, the “soft” endpoints of biochemical relapse-free survival and clinical relapse-free survival, and the “hard” endpoint of prostate cancer–specific mortality.

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer: Part 2

September 01, 2002

Despite the impact of prostate-specific antigen (PSA) testing on the detection and management of prostate cancer, controversy about its usefulness as a marker of disease activity continues. This review, based on a